Graham Cooper
Chairman at KEZAR LIFE SCIENCES, INC.
Net worth: - $ as of 2024-03-30
Profile
Graham K.
Cooper is currently the Chairman at Kezar Life Sciences, Inc. and an Independent Director at Beam Therapeutics, Inc. Previously, he served as the Executive Chairman at Applied Molecular Transport, Inc. from 2022 to 2023.
He also held the position of Director-Health Care Investment Banking at Deutsche Bank Securities, Inc. from 1997 to 2006.
Additionally, he was an Independent Director at Celladon Corp.
from 2013 to 2016 and at Unity Biotechnology, Inc. from 2017 to 2022.
Mr. Cooper was the Chief Financial Officer & EVP-Business Development at Geron Corp.
in 2012 and the Chief Financial Officer, Treasurer & Senior VP at Orexigen Therapeutics, Inc. from 2006 to 2011.
He served as the CFO, CAO, Head-Investor & Media Relations at Receptos LLC from 2014 to 2015.
Furthermore, he worked as an Accountant at Deloitte & Touche LLP from 1992 to 1995.
Mr. Cooper's education includes an undergraduate degree from the University of California, Berkeley and an MBA from Stanford Graduate School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BEAM THERAPEUTICS, INC.
-.--% | 2023-06-05 | 0 ( -.--% ) | - $ | 2024-03-30 |
KEZAR LIFE SCIENCES INC
-.--% | 2023-07-23 | 0 ( -.--% ) | - $ | 2024-03-30 |
Graham Cooper active positions
| Companies | Position | Start |
|---|---|---|
| KEZAR LIFE SCIENCES, INC. | Chairman | 2022-05-11 |
| BEAM THERAPEUTICS INC. | Director/Board Member | 2019-10-09 |
Former positions of Graham Cooper
| Companies | Position | End |
|---|---|---|
| APPLIED MOLECULAR TRANSPORT INC. | Chairman | 2023-03-07 |
| UNITY BIOTECHNOLOGY, INC. | Director/Board Member | 2022-05-24 |
| ASSEMBLY BIOSCIENCES, INC. | Director of Finance/CFO | 2019-03-31 |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Director/Board Member | 2016-02-29 |
| RECEPTOS INC | Director of Finance/CFO | 2015-08-26 |
Training of Graham Cooper
| University of California, Berkeley | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| GERON CORPORATION | Health Technology |
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| KEZAR LIFE SCIENCES, INC. | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
| BEAM THERAPEUTICS INC. | Health Technology |
| Private companies | 6 |
|---|---|
Deutsche Bank Securities, Inc.
 Deutsche Bank Securities, Inc. Investment Banks/BrokersFinance Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve. | Finance |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Bioniz Therapeutics, Inc.
 Bioniz Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA. | Commercial Services |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
- Stock Market
- Insiders
- Graham Cooper
